CSPC PHARMACEUT.GR. ADR4 Total Assets
CSPC PHARMACEUT.GR. ADR4 total assets. Based on the latest financial reports, CSPC PHARMACEUT.GR. ADR4 (CVGU) holds total assets worth €56.02 Billion EUR (≈ $65.50 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is CSPC PHARMACEUT.GR. ADR4 worth for the company's overall valuation and market capitalisation.
Total Assets of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Total assets of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. This chart illustrates how CSPC PHARMACEUT.GR. ADR4's total assets have evolved over time, based on quarterly financial data. See today's stock price for CSPC PHARMACEUT.GR. ADR4 for real-time trading data and today's change.
CSPC PHARMACEUT.GR. ADR4 - Asset Composition Analysis
CSPC PHARMACEUT.GR. ADR4 Total Assets Breakdown (December 2025)
CSPC PHARMACEUT.GR. ADR4 total assets breakdown as of December 2025. CSPC PHARMACEUT.GR. ADR4's total assets of €56.02 Billion consist of 47.7% current assets and 52.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €4.78 Billion | 10.2% |
| Inventory | €3.09 Billion | 6.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.77 Billion | 5.9% |
| Goodwill | €234.90 Million | 0.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how CSPC PHARMACEUT.GR. ADR4's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is CSPC PHARMACEUT.GR. ADR4's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC PHARMACEUT.GR. ADR4's current assets represent 47.7% of total assets in 2025, a decrease from 58.5% in 2021.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, down from 26.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
CSPC PHARMACEUT.GR. ADR4 Competitors by Total Assets
Key competitors of CSPC PHARMACEUT.GR. ADR4 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
CSPC PHARMACEUT.GR. ADR4 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.14 | 2.24 | 2.54 |
| Quick Ratio | 1.93 | 1.95 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €16.43 Billion | €12.50 Billion | €16.03 Billion |
CSPC PHARMACEUT.GR. ADR4 - Advanced Valuation Insights
This section examines the relationship between CSPC PHARMACEUT.GR. ADR4's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €46.70 Billion |
| Market Capitalization | $11.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CSPC PHARMACEUT.GR. ADR4's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CSPC PHARMACEUT.GR. ADR4's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC PHARMACEUT.GR. ADR4 (2021–2025)
The table below shows the annual total assets of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €46.70 Billion ≈ $54.59 Billion |
+5.20% |
| 2024-12-31 | €44.39 Billion ≈ $51.90 Billion |
-4.09% |
| 2023-12-31 | €46.28 Billion ≈ $54.11 Billion |
+10.80% |
| 2022-12-31 | €41.77 Billion ≈ $48.83 Billion |
+20.23% |
| 2021-12-31 | €34.74 Billion ≈ $40.62 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more